# Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-da-24-038-developing-regulated-therapeutic-and-diagnostic-solutions/  
Official notice: https://www.grants.gov/search-results-detail/347599

> National Institutes of Health offered grants of up to $300,000 to small businesses. Applications closed on February 14, 2025.

| Field | Value |
|---|---|
| Opportunity number | RFA-DA-24-038 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | February 14, 2025 |
| Award ceiling | $300,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.279 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.

## What the grant funds

This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this NOFO may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics)and (2) medical therapeutic and diagnostic devices, including software as a medical device. This NOFO strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.

## Questions people ask

### Is RFA-DA-24-038 still open?

No. It closed on February 14, 2025.

### Who can apply for Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)?

Closed February 14, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $300,000 each.

### Who has been funded under RFA-DA-24-038?

NIH RePORTER lists 5 projects funded under RFA-DA-24-038 in fiscal 2024 to 2026, at 5 institutions. The most were at Verisim Life, Inc., General Biophysics, LLC, Rafias LLC.

### Who has won Drug Use and Addiction Research Programs grants before?

The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.